Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
155
resultados
Última actualización
23/08/2025 [06:52:00]
Resultados 50 a 75 de 155
Resumen de: WO2025169954A1
Provided is a method for concentrating a lipid nanoparticle-containing liquid, the method comprising a step for filtering a lipid nanoparticle-containing liquid with a polyacrylonitrile-based ultrafiltration membrane.
Resumen de: WO2025169152A1
Disclosed is a process for the assembly of protein-polyphenol conjugate stabilized nanoemulsions (PPCSNEs) by a process that comprises: (a) combining (i) a first surfactant comprised of a pre-synthesized composite species made up of a biocompatible protein and polyphenolic species, (ii) a therapeutic amount of one or more psychedelic APIs, (iii) a triglyceride oil, and optionally (iv) a co- surfactant in a container, (b) high-shear mixing said ingredients in a container to form a coarse-emulsion product, and (c) subjecting the coarse-emulsion through a microfluidic device to produce a protein-polyphenol conjugate nanoemulsion containing a psychedelic agent.
Resumen de: WO2025168076A1
Disclosed herein are a peptoid compound and a peptoid conjugate such as a peptoid-lipid conjugate, and preparation methods therefor and the use thereof in a small molecule drug and nucleic acid delivery. Further disclosed herein are a lipid particle containing the peptoid-lipid conjugate, such as a liposome and a lipid nanoparticle, and a small molecule drug and/or a nucleic acid delivery composition containing the peptoid-lipid conjugate or the lipid particle. The peptoid-lipid conjugate, lipid particle, and small molecule drug and/or nucleic acid delivery composition that can be used for the small molecule drug and nucleic acid delivery of the present invention enable highly efficient compounding, protection, intracellular and targeted delivery and release of the small molecule drug and biomolecules, such as nucleic acids, in tissues and organs both in vitro and in vivo.
Resumen de: WO2025166993A1
A cationic lipid compound, a composition comprising the cationic lipid compound, and a use. A compound is as represented by general formula (I). Also provided are a cationic lipid compound comprising the compound, or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof. The present application also relates to an immune cell-targeted lipid nanoparticle, and a screening method therefor and a use thereof. Specifically disclosed is a use of the compound of formula (I), or the pharmaceutically acceptable salt, prodrug, or stereoisomer thereof in targeting immune cells, and also disclosed are a method for in vitro screening of lipid nanoparticles and a method for screening lipid nanoparticles suitable for delivering mRNA to various immune cells in vivo.
Resumen de: WO2025166967A1
The present invention relates to a polyethylene glycol lipid molecule containing a tocopherol structure, a lipid nanoparticle containing same, and a use thereof. Specifically, provided are a polyethylene glycol lipid molecule containing a tocopherol and its derivative structure as shown in formula (1), a lipid nanoparticle containing same, and a preparation method therefor and a use thereof. Compared with polyethylene glycol lipid molecules conventionally used in the art, lipid nanoparticles prepared from the polyethylene glycol lipid molecule shown in formula (1) can significantly improve the delivery efficiency and expression of nucleic acids.
Resumen de: WO2025166988A1
Disclosed is a method for treating nephropathy, which comprises targeted delivery of a nucleic acid composition by means of topical administration. Renal tubular cells are transfected with neutral LNPs by means of ureteral retrograde administration, or renal glomerular cells are transfected with positive and neutral LNPs by means of abdominal aorta administration, thereby better targeting renal lesion cells. The mRNA-LNP technology can be applied to the targeted delivery of a kidney-specific cell population by means of the selection of a drug delivery way, thereby achieving therapy for kidney genetic diseases.
Resumen de: WO2025166810A1
Disclosed is a supramolecular nanocomposite, comprising an active ingredient, a carrier, and a penetration enhancer, wherein the penetration enhancer is composed of an anionic glycolipid and a glycoside derivative. The supramolecular nanocomposite intermediate is prepared into a supramolecular nanocomposite (ophthalmic) preparation by adding an osmotic pressure regulator, a gel carrier, an in-situ gel carrier, or a gel initiator, a pH regulator, a thickener, a bacteriostatic agent, water for injection, and the like. Compared with the prior art, the supramolecular nanocomposite can achieve a higher drug loading capacity, stronger penetrability, high affinity, long-lasting efficacy, and low irritation, such that the medication safety and efficacy are improved for patients.
Resumen de: WO2025166401A1
There is provided a hybrid nanofibrous mat comprising electrospun nanofibers formed by electrospinning of a polymer mix and porous silica capsules dispersed throughout the electrospun nanofibers during the electrospinning, the porous silica capsules having a hydrophobic liquid core containing an active. There is also provided a method of producing a hybrid nanofibrous mat comprising providing porous silica capsules having a hydrophobic liquid core containing an active, forming an electrospinning solution comprising the porous silica capsules and an electrospinning polymer mix, homogenising the electrospinning solution to fully disperse the porous silica capsules, and electrospinning the electrospinning solution to form the hybrid nanofibrous mat.
Resumen de: US2025257354A1
Provided herein are compositions and methods related to tRNA therapeutics for treating vision loss and blindness.
Resumen de: US2025256978A1
The present invention enables us to achieve both further fine particle size reduction and uniformity of particle size distribution of metal oxide nanoparticles.The present invention is a method for producing metal oxide nanoparticles that consists of a process for obtaining metal oxide nanoparticles by mixing a supercritical, subcritical, or gas phase aqueous material and an organometallic complex solution, wherein the mixing time is controllable within the range of 0.015 s to 380 s and the diameter of at least one of the average primary particle diameter or the crystallite diameter of the nanoparticles can be controlled within the range of 1.0 nm to 9.0 nm, and the coefficient of variation of the diameter can be controlled within 0.5 nm or less by controlling the mixing time. The resulting nanoparticles encompass metal elements capable of forming organometallic complexes. Additionally, the organic molecules are strongly bonded to the most unstable surface.
Resumen de: US2025256972A1
The present disclosure relates to a nanostructure containing: 50 to 80% (w/w) of a magnetic material; and 20 to 50% (w/w) of calcium silicate. The present disclosure further relates to a nanocomposite containing the nanostructure as disclosed herein with an additive. The present disclosure also provides a gel containing the nanostructure or the nanocomposite and additives, and methods thereof.
Resumen de: US2025256248A1
An apparatus may be for producing nanocarriers and/or nanoformulations. A process may be for producing a nanocarrier and/or a nanoformulation with this apparatus. According to the preparation, a first liquid phase and a second liquid phase are mixed first to give a primary mixture using a static mixer. In a subsequence mixing step the primary mixture is diluted with a third liquid. An aspect of apparatus may be that the arrangement of the static mixer inside a linear pipe conducting a third liquid phase. Thus, the primary mixture exiting the mixer is instantaneously diluted with to give secondary mixture. The volume flow of the third mixture is chosen larger than the volume flow of the primary mixture. By these measures, nanocarriers with improved morphology and homogeneity are produced. Encapsulation efficiency was enhanced as well.
Resumen de: US2025255978A1
Disclosed herein are compositions comprising nanoparticles comprising a carrier polypeptide and a double-stranded oligonucleotide, wherein the carrier polypeptide comprises a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment; and wherein the molar ratio of the carrier polypeptide to the double-stranded oligonucleotide in the nanoparticle composition is less than about 6:1, along with methods of making and using such nanoparticles. Further described are methods of treating a subject with a cancer, such as a chemotherapeutic drug resistant cancer comprising administering to the subject a composition comprising nanoparticles, the nanoparticles comprising a carrier polypeptide comprising a cell-targeting segment, a cell-penetrating segment, and an oligonucleotide-binding segment; a double-stranded oligonucleotide bound to the oligonucleotide-binding segment; and a chemotherapeutic drug bound to the double-stranded oligonucleotide. Also described are pharmaceutical compositions, articles of manufacture, and kits comprising the described nanoparticles.
Resumen de: US2025255971A1
The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.
Resumen de: US2025255984A1
The anionic manganese oxide nanoparticle nucleic acid scavengers are biodegradable anionic scavengers with low cytotoxicity, which are able to scavenge (bind) cell-free nucleic acids (e.g., extracellular ssRNA, dsRNA, and unmethylated DNA), providing treatment for various medical conditions. The main component of the scavenger is manganese oxide, which may be synthesized by using a manganese compound (e.g., manganese acetate) and an acid (e.g., tannic acid) at high temperature (e.g., 100-150° C.). Synthesis may be performed by mixing a manganese compound and an acid in water forming a mixture, which is stirred, heated, and allowed to cool. The anionic manganese oxide nanoparticles are extracted from the cooled mixture. The typical size of the resultant nanomaterials ranges from 30 to 100 nm; the zeta potential of the as-prepared nanomaterials is about −20 mV. The nanoparticles have various uses, including administration to a subject to treat inflammation or to treat cancer.
Resumen de: US2025255974A1
An object is to provide a technique that improves the poor solubility of a compound of formula (1) in water and further suppresses the cytokine excessive release action and bone marrow toxicity of the compound of formula (1). This object is achieved by a complex comprising a modified polysaccharide containing a hydrophobic group, and a compound represented by formula (1).
Resumen de: US2025255829A1
This disclosure relates to nanoparticles comprising a cardiovascular agent, a PD-L1 binding agent on the surface, and optionally an anticancer agent. In certain embodiments, the cardiovascular agent is an inhibitor of cholesterol acyltransferase such as avasimibe. In certain embodiments, the nanoparticles comprise a hyaluronic acid core. In certain embodiments, this disclosure relates to methods of treating or preventing cancer and/or atherosclerosis, or other cardiovascular disease by administering an effective amount of nanoparticles disclosed herein to a subject in need thereof.
Resumen de: US2025255962A1
A gold nanocluster of the formula Au22(Lys-Cys-Lys)16, wherein Lys-Cys-Lys is lysine-cysteine-lysine, and methods for synthesis, are provided. The gold nanocluster effectively produces Type I ROS and functions as photosensitizer, and has utility in applications such as, but not limited to, biomedical applications and photocatalysis. The gold nanocluster may be useful in photodynamic therapy (PDT) and as a radiosensitizer in cells and tissues for treating diseases such as certain cancers.
Resumen de: US2025255850A1
Method and compositions that comprise an agent that reduces nNOS activity and uses thereof in the treatment of a disease or condition in which a beneficial clinical effect is achieved by reduction in neuronal nitric oxide synthase (nNOS) activity are provided.
Resumen de: US2025255828A1
The invention is directed to the field of therapeutic formulations, in particular to lyophilization of a therapeutic cargo molecule, such as RNA. The invention provides a method for lyophilization of a molecule. The present disclosure further describes a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine, a therapeutic and a kit or kit of parts. Moreover, the disclosure herein provides a novel lyophilization excipient that protects the composition from degrading when, for example, lyophilizing RNA. The use of the inventive method further includes the manufacture of a composition that can be used after lyophilization with equivalent therapeutic effect and composition integrity.
Resumen de: US2025255817A1
A nanoprecipitation or nanoemulsion method forms a polynucleotide delivery particle, wherein the polynucleotide delivery particle contains at least one poly(lactic-co-glycolide), at least one cationic surfactant, at least one polynucleotide, and optionally at least one additive, wherein the poly(lactic-co-glycolide) has a weight average molecular weight Mw of 1000 to 9500 g/mol measured via gel permeation chromatography using polystyrene standards and chloroform. The polynucleotide delivery particle as an additional component in an oral drug delivery composition or a parenteral drug delivery composition supports the beneficial characteristics of the application as a medicament.
Resumen de: US2025255816A1
Disclosed herein are polysulfide microparticles that include a varying monomer composition. The monomer composition can control properties of the microparticles, such as crystallinity, which can aid in the production and stability of the microparticles. An example microparticle includes a polymer derived from monomers of propylene sulfide (PS) and ethylene sulfide (ES). The microparticles disclosed herein can be useful in drug delivery applications, such as treating inflammatory diseases. Also disclosed are methods of making the polysulfides and methods of making the microparticles.
Resumen de: US2025255815A1
The present disclosure relates to compositions for expression of a constitutively-active cyclic GMP-AMP synthase in cells of a mammalian subject and uses thereof for enhancing immunogenicity of mRNA vaccines. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising one or both of a lysophosphatidylcholine (LPC) compound and a pathogen recognition receptor agonist.
Resumen de: US2025255831A1
A method of preparing an abuse deterrent pharmaceutical composition having a drug-containing core enclosed by one or more metal oxide materials is provided. The method includes the sequential steps of (a) loading the particles comprising the drug into a reactor, (b) applying a vaporous or gaseous metal precursor to the particles in the reactor, (c) performing one or more pump-purge cycles of the reactor using inert gas, (d) applying a vaporous or gaseous oxidant to the particles in the reactor, and (e) performing one or more pump-purge cycles of the reactor using inert gas. This produces an abuse deterrent pharmaceutical composition comprising a drug containing core enclosed by one or more metal oxide materials.
Nº publicación: US2025255825A1 14/08/2025
Solicitante:
COUNCIL FOR SCIENT AND INDUSTRIAL RESEARCH [ZA]
COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH
Resumen de: US2025255825A1
The current invention relates to a polymer-lipid nanocomplex for enhanced aqueous solubilisation and absorption of hydrophobic active compounds, a process for producing such a nanocomplex, and to methods of use of such a nanocomplex.
BOPI
Sede Electrónica
